Participant Age Range
18 years and older
“A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)”
This study will compare the efficacy and safety in of LOXO-305 administered as a continuous monotherapy with Investigator’s choice of standard of care IdelaR or BR. The patient population will have received prior BTK inhibitor therapy as part of any number of prior therapies. Therefore, the patient population is heterogeneous in regards to treatment exposure and future prognosis.
Amol H. Rao, MD
Hematology-Oncology, Internal Medicine
Fountain Valley, Laguna Hills